Literature DB >> 8016189

Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret.

H E Marr1, P T Davey, E A Boyle, P R Blower.   

Abstract

In ferrets, the highly selective 5-HT3 receptor antagonist, granisetron, abolished or reduced emesis induced by cisplatin (10 mg/kg i.v.) or whole body X-irradiation (50 Gy in 10.4 min) in a dose-dependent manner when administered by a variety of routes (intravenous, per os, subcutaneous, intramuscular). Complete protection from vomiting and retching was achieved with 0.5 mg/kg i.v. or p.o. granisetron. Granisetron (0.5 mg/kg i.v.) was also effective when given 6 h before cisplatin, completely protecting 50% of ferrets for a total of 10 h. Following repeat dosing, for either 4 days i.v. or 10 days p.o. before emetic challenge, granisetron (0.5 mg/kg) still retained its antiemetic activity on the 5th or 11th day. Prior treatment with cyclophosphamide (80 mg/kg i.v.) resulted in a significantly shorter time to the onset of vomiting after exposure to X-irradiation. Granisetron, but not saline, abolished vomiting and nausea when given as intervention after this combined emetic regimen. These results show that granisetron has potential flexibility for administration via a variety of different routes and also a long duration of action when used as an antiemetic against a wide range of cytostatic agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016189     DOI: 10.1159/000139191

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

1.  Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial.

Authors:  Daiki Tsuji; Yong-Il Kim; Keisei Taku; Shigeru Nakagaki; Yoshito Ikematsu; Hiromi Tsubota; Masato Maeda; Naoya Hashimoto; Masayuki Kimura; Takashi Daimon
Journal:  Support Care Cancer       Date:  2011-05-18       Impact factor: 3.603

2.  The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets.

Authors:  H E Marr; P T Davey; E A Boyle; P R Blower
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 3.  Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonists.

Authors:  N Percie du Sert; J A Rudd; C C Apfel; P L R Andrews
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-28       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.